



TRANSMITTAL FORM

to be used for all correspondence after initial filing)

Application Number		10/539,512 ✓
Filing Date		June 17, 2005
First Named Inventor		Mark E. Fraley
Art Unit		1625
Examiner Name		To be determined
Attorney Docket Number		21293YP
Total Number of Pages in This Submission	-	

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
Remarks - Seven references enclosed - Explanation of Relevance of Non-English Documents Under 37 C.R.F. 1.98(a)(3)(i)		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Name	David A. Muthard	Registration No. (Attorney/Agent)	35,297
Signature			Date 1/23/2006

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this date: January 23, 2006

Typed or printed name	David A. Muthard		
Signature		Date	January 23, 2006



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mark E. Fraley

Serial No. 10/539,512

Filed: June 17, 2005

For: MITOTIC KINESIN INHIBITORS

Art Unit: 1625Examiner: To be determined

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By 

Date

1/23/06

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: David A. Muthard
Attorney _____ For Applicant(s)

Reg. No. 35,297
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732)594-3903

Date: January 23, 2006



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul J. Coleman, et al.

Serial No.: 10/539,512 Case No.: 21293YP

Filed: June 17, 2005

For: MITOTIC KINESIN INHIBITORS

Art Unit:

1617

Examiner:

To be determinedCommissioner of Patents
Alexandria, VirginiaEXPLANATION OF RELEVANCE OF NON-ENGLISH DOCUMENTS UNDER 37 C.F.R. 1.98(a)(3)(i)

Sir:

Applicants respectfully note that two (2) of the documents listed on the USPTO 1449 form submitted herewith are not in the English language and a copy of English translations of those documents are not within the possession, custody or control of Applicants, and, to the Applicants knowledge, are not readily available. Below is a concise explanation of the relevance of those non-English documents:

The Russian language publication in *Kimiko Farmatseuticheskii Journal* discloses N-alkyl and N-alkynyl 2,4-diphenyl 1,2,3,6-tetrahydropyridine compounds that are described as analgesic and psychotropic agents

The German language scientific publication in *Helvetica Chimica Acta* discloses 2-aryl substituted hydrobenzo[a]quinoline compounds, which are described as having analgesic and anti-inflammatory properties.

The instant invention discloses certain 2,4-disubstituted 1,2,3,6-tetrahydropyridine compounds that are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cancer.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

By: DATE: 1/23/06

Respectfully submitted,

By: 

David A. Muthard
Reg. No. 35,297
Attorney for Applicant(s)
MERCK & CO., INC.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3903

Date: January 23, 2006

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

COMPLETE IF KNOWNA circular stamp from the Intellectual Property Office (IPO). The text "O I P E" is at the top, "JAN 26 2006" is in the center, and "INTELLECTUAL PROPERTY OFFICE" is at the bottom.

Sheet	1	of	2	Attorney Docket Number	21293YP
-------	---	----	---	------------------------	---------

[illegible][illegible]

Examiner Signature	/Binta Robinson/	Date Considered	06/19/2008
--------------------	------------------	-----------------	------------

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/539,512
---------------------------	------------

Filing Date	June 17, 2005
--------------------	---------------

First Named Inventor	Mark E. Fraley
-----------------------------	----------------

Group Art Unit	1625
----------------	------

Examiner Name	To be determined
---------------	------------------

Attorney Docket Number 21293YP



2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Lansbury, JACS, 90 (2), pg. 536-7 (1968)

/BR/

Bruderer, et al., *Helv. Chim. Acta.*, 47, pgs. 1852-9 (1964)

/BR/

D. A. Comins, *Tetrahedron Letters*, 33, pgs. 6299-6302 (1992)

/BR/

T. D. Sokolova, et al., *Chemistry of Heterocyclic Compounds*, 33(6), pgs. 676-9 (1997)

/BR

K. D. Praliev, et al., Khim. -Farm. Zh., 17(9), pgs. 1053-5 (1983)

/BR

N. Yokoyama, et al., J. Med. Chem., 22(5), pgs. 537-553 (1979)

Examiner
Signature

/Binta Robinson/

Date
Considered

06/19/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., -7/12/2005